Therefore, the analysis of EGFR and RAS/BRAF mutations in plasma using the IdyllaTM platform is feasible and reliable in clinical practice and allows the selection of the best treatment for our patients, especially those with metastatic lung adenocarcinomas and colon cancer. The gene discussed is BRAF; the disease is colonic neoplasm.